Figure 1.
Kaplan-Meier survival curves for OS and TTNT. (A) OS from initiation of daratumumab. (B) TTNT or death from initiation of daratumumab. (C) TTNT or death from initiation of daratumumab for patients with initial dFLC ≥5 mg/dL.

Kaplan-Meier survival curves for OS and TTNT. (A) OS from initiation of daratumumab. (B) TTNT or death from initiation of daratumumab. (C) TTNT or death from initiation of daratumumab for patients with initial dFLC ≥5 mg/dL.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal